None
Quote | Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE:TAK)
Last: | $13.16 |
---|---|
Change Percent: | -0.08% |
Open: | $13.16 |
Close: | $13.16 |
High: | $13.225 |
Low: | $13.12 |
Volume: | 1,286,645 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE:TAK)
2024-04-09 10:48:41 ET Summary Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome market is expected to reach $1 billion by 2036. Re...
FY23 Investment Brings Program Total to Nearly $55 Million, Welcoming Eight New Grant Partners Company Continues to Advance Equity in Under-Resourced Communities with a Focus on Nutrition and STEM Education Takeda Publishes its Annual U.S. Community Impact Report Highlighting Prog...
Message Board Posts | Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE:TAK)
Subject | By | Source | When |
---|---|---|---|
Just saying, | Boing x 2 | investorshub | 01/31/2023 6:08:12 PM |
Takedas Pipeline Has Potential to Contribute Significantly to | Phosphene | investorshub | 12/09/2020 4:21:27 AM |
Japan's Takeda eyes new focus on vaccines after | Phosphene | investorshub | 11/29/2020 11:24:36 PM |
MIT-Takeda program launches | Phosphene | investorshub | 11/29/2020 11:22:36 PM |
Takeda shares tumbled as much as 9.3 percent | rising | investorshub | 05/08/2018 1:19:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
FY23 Investment Brings Program Total to Nearly $55 Million, Welcoming Eight New Grant Partners Company Continues to Advance Equity in Under-Resourced Communities with a Focus on Nutrition and STEM Education Takeda Publishes its Annual U.S. Community Impact Report Highlighting Prog...
2024-04-05 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms ADZYNMA (apadamtase alfa /cinaxadamtase alfa) is the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for People with cTTP Takeda (...